Dupilumab as an effective therapy for eosinophilic esophagitis in pediatric patients weighing less than 15 kilograms

杜皮鲁玛 医学 嗜酸性食管炎 皮肤病科 不利影响 食管炎 特应性皮炎 内窥镜检查 内科学 临床试验 过敏 胃肠病学 上内镜检查 回顾性队列研究 随机对照试验 过敏性 质子抑制剂泵 入射(几何) 儿科 年轻人
作者
Sindhura Kasturi,Tanaz Danialifar,Thirumazhisai S. Gunasekaran,Nick Shillingford,Paul Zamiara,Vrinda Bhardwaj,Melinda Braskett
出处
期刊:JPGN reports [Lippincott Williams & Wilkins]
卷期号:7 (2): 185-191
标识
DOI:10.1002/jpr3.70129
摘要

Objectives: Eosinophilic esophagitis (EoE) is a type 2 cytokine-mediated chronic inflammatory condition leading to esophageal dysfunction. Dupilumab blocks IL-4 and IL-13 signaling, which are key inflammatory mediators in EoE and other allergic disorders. In the United States, the Food and Drug Administration (FDA) has approved the use of dupilumab in children and adults with doses that vary by age, weight and indication. Dupilumab is currently approved for EoE in children above 1 year of age and weight greater than 15 kg. There is an unmet need to extend the use of dupilumab for children with EoE below this weight threshold and there is a paucity of data. We seek to describe the safety and efficacy of dupilumab in treating EoE at doses approved for eczema in children weighing less than 15 kg. Methods: The retrospective chart review was approved by the Institutional Review Board (IRB) at Children's Hospital Los Angeles. A search for patients with a diagnosis of EoE treated with dupilumab for any indication between 2019 and 2024 identified four patients weighing less than 15 kg. Results: This report highlights a single-center experience with dupilumab in four patients with EoE weighing less than 15 k. All patients had clinical improvement. Three patients had follow-up endoscopy demonstrating endoscopic and histologic improvement. No significant adverse effects were noted. Conclusions: In our limited experience, dupilumab was safe and effective in four EoE patients weighing less than 15 kg using the FDA-approved dose for atopic dermatitis. Prospective trials are needed to optimize dosing and provide comprehensive safety and efficacy data.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
传奇3的应助被蓝桉采纳,获得10
刚刚
Miracle_wh完成签到 ,获得积分10
刚刚
Ddurian发布了新的文献求助10
刚刚
潇洒的以柳完成签到 ,获得积分10
1秒前
3秒前
长易木完成签到,获得积分10
3秒前
3秒前
Ljz完成签到,获得积分10
5秒前
5秒前
是述不是沭完成签到,获得积分0
5秒前
糊涂的天晴完成签到,获得积分10
5秒前
6秒前
n01W97的应助被旺旺采纳,获得20
6秒前
杨希完成签到,获得积分10
8秒前
颖火虫2588完成签到,获得积分10
8秒前
nanaimo完成签到 ,获得积分10
9秒前
元素搬运工完成签到,获得积分10
9秒前
10秒前
慕青的应助被Chris采纳,获得10
10秒前
11秒前
vc发布了新的文献求助10
11秒前
山雾有风完成签到,获得积分10
11秒前
12秒前
希望天下0贩的0的应助被cheng采纳,获得10
13秒前
可耐的以冬完成签到,获得积分10
13秒前
万能图书馆的应助被汪一兰采纳,获得10
13秒前
14秒前
15秒前
初景发布了新的文献求助10
16秒前
WHL完成签到,获得积分10
16秒前
852的应助被木风采纳,获得10
17秒前
秋风的应助被yanzi采纳,获得10
17秒前
冷艳寻菡完成签到,获得积分10
17秒前
单薄翠绿发布了新的文献求助30
17秒前
马浩然发布了新的文献求助10
17秒前
18秒前
19秒前
搜集达人的应助被susu采纳,获得10
20秒前
20秒前
Jasper的应助被majiaqi采纳,获得10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179039
求助须知:如何正确求助?哪些是违规求助? 9569680
关于积分的说明 21805951
捐赠科研通 7774135
什么是DOI,文献DOI怎么找? 3432981
关于科研通互助平台的介绍 2556897
邀请新用户注册赠送积分活动 2478640